Table 3 The most frequent 4th level ATC sub-classes according to prescription goals
From: Drug prescription goals in primary care: a cross-sectional study
Goal | ATC sub-class | n (%) |
|---|---|---|
Mortality (n = 429) | Platelet aggregation inhibitors excl. Heparin (B01AC) | 51 (11.9%) |
HMG CoA reductase inhibitors (statin) (C10AA) | 48 (11.2%) | |
Beta blocking agents, selective (C07AB) | 32 (7.5%) | |
ACE inhibitors, plain (C09AA) | 30 (7.0%) | |
Angiotensin II antagonists, plain (C09CA) | 22 (5.1%) | |
Morbidity (n = 1128) | HMG CoA reductase inhibitors (statin) (C10AA) | 106 (9.4%) |
Vitamin D and analogues (A11CC) | 74 (6.6%) | |
ACE inhibitors, plain (C09AA) | 65 (5.8%) | |
Beta blocking agents, selective (C07AB) | 59 (5.2%) | |
Calcium channel blockers, dihydropyridine derivatives (C08CA) | 54 (4.8%) | |
Platelet aggregation inhibitors excl. Heparin (B01AC) | 54 (4.8%) | |
Cure (n = 587) | Penicillins with extended spectrum (J01CA) | 59 (10.1%) |
Glucocorticoids (H02AB) | 38 (6.5%) | |
NSAID propionic acid derivatives (M01AE) | 31 (5.3%) | |
Selective serotonin reuptake inhibitors (N06AB) | 29 (4.9%) | |
Imidazole and triazole derivatives for topical use (D01AC) | 25 (4.3%) | |
Symptom (n = 2183) | Anilidesa (N02BE) | 559 (25.6%) |
NSAID propionic acid derivatives (M01AE) | 121 (5.5%) | |
Proton pump inhibitors (A02BC) | 113 (5.2%) | |
Corticosteroids for nasal use (R01AD) | 105 (4.8%) | |
Other drugs for functional gastrointestinal disorders (A03AX) | 78 (3.6%) | |
Quality of life (n = 534) | Anilidesa (N02BE) | 51 (9.6%) |
Benzodiazepine derivatives (N05BA) | 32 (6.0%) | |
Benzodiazepine related drugs (N05CF) | 30 (5.6%) | |
Selective serotonin reuptake inhibitors (N06AB) | 30 (5.6%) | |
Proton pump inhibitors (A02BC) | 25 (4.7%) | |
Functioning (n = 91) | Other anti-inflammatory and antirheumatic agents, non-steroids (M01AX) | 7 (7.7%) |
Vitamin D and analogues (A11CC) | 4 (4.4%) | |
Anilidesa (N02BE) | 4 (4.4%) | |
Other nasal preparations (R01AX) | 4 (4.4%) | |
Other (n = 60) | Progestogens and estrogens, fixed combinations (G03AA) | 9 (15.0%) |
Progestogens and estrogens, sequential preparations (G03AB) | 6 (10.0%) | |
Bacterial and viral vaccines, combined (J07CA) | 3 (5.0%) | |
None (n = 24) | Vitamin D and analogues (A11CC) | 4 (16.7%) |
Antiseptics biguanides and amidines (D08AC) | 3 (12.5%) | |
Natural opium alkaloids (N02AA) | 2 (8.3%) | |
Anilidesa (N02BE) | 2 (8.3%) | |
Mucolytics (R05CB) | 2 (8.3%) |